CONTINUE TO SITE
OR WAIT 15 SECS
India-based Cipla has announced an exclusive licensing agreement with Taiwan-based Formosa Pharmaceuticals for
The Ministry of Health, Labour, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD
Japan-headquartered Astellas Pharma Inc. and Yaskawa Electric Corporation have signed a definitive a
A new ‘nanoball’ vaccine platform developed by experts in Japan will be tested as part of new rese
Taiwan-based Formosa Group Executive Committee member and Chairman Sandy Wang, who leads the group's bio and e
Infinitus (China) Company has secured approval for its Sino-British Joint Laboratory on Health and Ageing proj
ABL Diagnostics, a Euronext-listed leader in molecular diagnostics, has announced an exclusive distribution ag
Proteomics International Laboratories, a pioneer in precision diagnostics, has announced the launch of
Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provide
Avance Clinical, a leading full-service global Contract Research Organization (CRO) specialising in high-quali
Mitigating PATENT CLIFF Fallout
Monoclonal antibodies (mAbs) represent a $279.8 billion market, projected to reach $804 billion by 2033, according to a report from Dimension Market Research. With patents for many of these valuable drugs set to expire in the coming years, the industry faces significant challenges. In this story, we examine 11 blockbuster mAbs whose patents will expire between 2025 and 2030. These expirations, affecting some of pharma's biggest players, will have a major impact on the market and their revenue streams.
ISPOR 2025
ISPOR
info@ispor.org https://www.ispor.org/conferences-education/event/2025/05/13/default-calendar/ispor-2025Montreal
SINGLE-USE TECHNOLOGIES VI 2025
ECI
info@engconfintl.org https://engconf.us/conferences/biotechnology/single-use-technologies-vii/Malta
